Current Scientific Research in Biomedical Sciences
ISSN: 2689-6044

Academic Strive
Researcher's perception is our reality

Research Article *Volume 6 Issue 1*

Classic Galactosemia: Understanding the Mechanisms, Diagnostic Challenges, Clinical Manifestations, and Implications for Management

Stephanie KN[1]*, Mmasichukwu B[2], Janemary OC[3] and Chinonso OV[3]

[1]Department of Human Nutrition, Family & Consumer Sciences, Texas State University, USA

[2]Department of Human Development & Family Sciences, Family & Consumer Sciences, Texas State University, USA

[3]Department of Nutrition & Dietetics, University of Nigeria, Nigeria

***Corresponding author:** Kennedy-Ndaw Stephanie, Department of Human Nutrition, Family & Consumer Sciences, Texas State University, San Marcos, USA, Email: stephkendaw@gmail.com

Received Date: October 07, 2024; **Published Date:** November 15, 2024

Abstract

Classic Galactosemia (CG) is an autosomal recessive disorder caused by mutations in the galactose-1-phosphate uridyltransferase (GALT) gene, leading to disruptions in the Leloir pathway of galactose metabolism. The buildup of galactose and its metabolites, such as galactitol and galactonate, contributes to a wide range of clinical manifestations, including liver disease, neurological impairment, and ovarian insufficiency. This paper explores the biochemical mechanisms underpinning CG, its pathophysiology, diagnosis, and clinical impact of GALT mutations. The study presents data from a recent multicenter cohort analysis, showing that the Q188R mutation is associated with a significantly higher prevalence of cognitive impairment (75%, $p < 0.01$) and ovarian insufficiency (50%, $p < 0.05$) compared to the S135L (20% and 10%) and N314D (15% and 5%) mutations. These findings suggest that genotype plays a critical role in the severity of CG and patient outcomes. Early diagnosis and dietary intervention are crucial, but research indicates that some complications persist even with treatment. This review emphasizes the need for further therapeutic advances to improve patient outcomes.

Keywords: Classic Galactosemia; GALT Mutation; Leloir Pathway; Galactose Metabolism; Pathophysiology; Diagnosis

Abbreviations

CG: Classic Galactosemia; GALT: Galactose-1-Phosphate Uridyltransferase; GALK: Galactokinase; GALE: Galactose 4-Epimerase.

Introduction

Classic Galactosemia (CG) is a rare autosomal recessive disorder caused by mutations in the galactose-1-phosphate uridyltransferase (GALT) gene, resulting in impaired galactose metabolism. The condition is characterized by the accumulation of galactose and its metabolites, which cause toxic effects in various organs. Galactose, an organic aldohexose, plays a role as both a metabolic substrate and a structural component in macromolecules. The body's ability to properly metabolize galactose is crucial, as it is present in significant amounts in breast milk and many infant formulas. Consequently, CG often presents shortly after birth when infants are exposed to galactose-containing diets.

The metabolism of galactose occurs primarily through the Leloir pathway, where it is converted into glucose for energy and other cellular processes. The first enzyme in this pathway is galactokinase (GALK), which phosphorylates galactose to produce galactose-1-phosphate (Gal-1-P). GALT then catalyzes the conversion of Gal-1-P to uridine diphosphate galactose (UDP-Gal), which is subsequently converted to uridine diphosphate glucose (UDP-Glc) by UDP-galactose 4-epimerase (GALE) [1]. Mutations in the GALT gene lead to deficient or absent enzyme activity, resulting in the accumulation of Gal-1-P and other toxic metabolites like galactitol and galactonate. This impairment in galactose metabolism underpins the pathophysiology of CG, with effects seen across multiple organs [2].

Patients with CG experience symptoms ranging from liver dysfunction, renal failure, and cataracts to cognitive impairments and primary ovarian insufficiency [3]. The severity of symptoms depends on the nature of the GALT mutation and the residual enzyme activity [4]. Given the range of mutations that can occur in the GALT gene and the varying phenotypic presentations, understanding the underlying mechanisms and clinical implications of CG is vital for its diagnosis and management.

Mechanisms of Galactose Metabolism

The Leloir Pathway

The Leloir pathway is the primary route for galactose metabolism in humans. After ingestion, galactose is absorbed by enterocytes in the small intestine and transported to the liver, where the majority (approximately 88%) is metabolized [1]. The first step in the pathway involves the phosphorylation of galactose by galactokinase (GALK) to produce galactose-1-phosphate (Gal-1-P). GALT, the second enzyme in the pathway, catalyzes the transfer of a uridyl group from UDP-glucose (UDP-Glc) to Gal-1-P, forming UDP-galactose (UDP-Gal) and glucose-1-phosphate (Glc-1-P). Finally, UDP-Gal is converted to UDP-Glc by UDP-galactose 4-epimerase (GALE) [5].

Mutations in the GALT gene disrupt this process, causing an accumulation of Gal-1-P and related metabolites, which contribute to the clinical manifestations of CG. The nature of the GALT mutation determines the residual enzyme activity, with amorphic mutations resulting in complete loss of function and hypomorphic mutations allowing for some residual activity The severity of the disease correlates with the degree of enzyme deficiency.

Alternative Pathways of Galactose Metabolism

In the absence or deficiency of GALT, galactose is metabolized through alternative pathways. The polyol pathway converts galactose to galactitol via aldose reductase. Galactitol is osmotically active and cannot be further metabolized, leading to its accumulation within cells, which can result in cataracts, particularly in GALK- and GALT-deficient individuals [6]. The oxidative stress and hyperosmotic effects caused by intracellular galactitol contribute to cellular damage, particularly in the lens of the eye [7]. Galactose can also be oxidized to galactonate through the action of galactose dehydrogenase. Galactonate may either be excreted in the urine or metabolized further through the pentose phosphate pathway [5]. While these alternative pathways serve as compensatory mechanisms for galactose metabolism in CG, they contribute to the buildup of toxic metabolites and exacerbate clinical symptoms [4].

Clinical Manifestations of Classic Galactosemia

Diagnosis and Genetic Variants CG typically presents shortly after birth when an infant is exposed to a galactose-containing diet. Symptoms such as vomiting, diarrhea, weight loss, jaundice, hepatomegaly, hypotonia, and sepsis develop rapidly, and if left untreated, can lead to life-threatening complications [2]. Early diagnosis through newborn screening is crucial for prompt intervention, as dietary management can mitigate some of the acute symptoms.

The GALT gene, located on chromosome 9p13, spans 11 exons and encodes a 379-amino-acid polypeptide [8]. Approximately 300 mutations, polymorphisms, and variants of unknown significance have been identified in the GALT gene, leading to varying degrees of enzyme deficiency [9]. The most common mutation, Q188R, accounts for the majority of CG cases in Caucasian populations [4]. Other notable variants include S135L, commonly found in Black populations, and N314D, associated with the Duarte galactosemia variant.

Long-Term Complications

Despite early dietary intervention, patients with CG are at risk of developing long-term complications, including cognitive impairment, speech difficulties, and primary ovarian insufficiency (POI) in females [3]. The exact mechanisms underlying these complications are not fully understood but may be related to residual galactose metabolites, impaired glycoprotein biosynthesis, and secondary effects of the disease on various organs and tissues (Table 1).

Mutation	Population Prevalence	GALT Activity	Clinical Features
Q188R	Caucasian	Absent/Low	Severe symptoms, risk of E. coli sepsis, cognitive impairment
S135L	Black	Reduced	Variant galactosemia, potential acute symptoms but rare long-term complications
N314D	Global	Partial	Duarte variant, milder symptoms, reduced risk of long-term complications

Table 1: Summary of GALT Mutations and Associated Clinical Features.

Statistical Analysis

A recent multicenter cohort study involving 200 patients with CG analyzed the relationship between genotype and clinical phenotype, with a focus on the Q188R, S135L, and N314D mutations [10]. The results showed that patients with the Q188R mutation had significantly higher rates of cognitive impairment (75%, $p < 0.01$) and ovarian insufficiency (50%, $p < 0.05$) compared to those with other mutations [4]. Conversely, the S135L mutation was associated with milder symptoms and fewer long-term complications, supporting the importance of genotype-specific therapeutic interventions [7].

Results

The Q188R mutation was found to be the most prevalent, accounting for 48% of the cases, followed by N314D (20%) and S135L (15%). Patients with the Q188R mutation exhibited significantly higher rates of cognitive impairment ($p<0.01$) and POI ($p<0.05$) compared to those with the S135L and N314D variants. The N314D mutation, associated with the Duarte variant, showed milder clinical features, with fewer long-term complications ($p < 0.01$) (Table 2).

Mutation	Cognitive Impairment (%)	POI in Females (%)	Overall Complications (%)
Q188R	85	60	90
S135L	20	10	30
N314D	10	5	15

Table 2: Clinical Outcomes Based on GALT Mutation Type.

The results indicate that GALT mutation type is strongly associated with clinical severity in CG, with the Q188R mutation being predictive of more severe outcomes. The findings support the need for mutation-specific interventions to improve patient care [11,12].

Conclusion

The current understanding of CG and its management emphasizes the need for early diagnosis and intervention. The results from the recent cohort study reinforce the importance of genotype in determining the clinical outcomes of CG, with the Q188R mutation showing significantly higher rates of cognitive impairment (75%) and ovarian insufficiency (50%) compared to other mutations (S135L: 20% cognitive impairment and 10% ovarian insufficiency; N314D: 15% cognitive impairment and 5% ovarian insufficiency). These findings highlight the need for genotype-specific approaches to treatment and underscore the limitations of current dietary interventions in preventing long-term complications. The data suggest that patients with the Q188R mutation may require closer monitoring and potentially different therapeutic strategies. Further research is necessary to explore novel therapeutic interventions targeting both the metabolic and genetic components of CG, such as enzyme replacement and gene therapy. The integration of genotype-specific treatments could significantly improve long-term outcomes and quality of life for CG patients.

References

1. Broomfield A, Brain C, Grunewald S, Champion MP (2020) Galactosaemia: An evolving perspective. Journal of Inherited Metabolic Disease 43(4): 708-719.

2. Sinanovic O, Vranjes V, Hasanbegović M (2022) Galactosemia: An updated overview on the diagnosis and treatment strategies. Archives of Medical Science 18(5): 1298-1307.

3. Los E, Ford GA (2020) Galactose 1 Phosphate Uridyltransferase Deficiency. In: Stat Pearls (Ed.), StatPearls Publishing, Treasure Island.

4. Benito C, Cuadras D, Gutiérrez L (2021) Classic

galactosemia: A comprehensive review. European Journal of Pediatrics 180(7): 2067-2080.

5. Thoden JB, McCarthy D, Schaffer CG (2020) Galactose metabolism: Structural insights into the Leloir pathway. Frontiers in Molecular Biosciences 7(130).

6. Erven BV, Berry GT, Lee PJ (2021) Galactose and galactitol metabolism in galactosemia: Implications for pathophysiology and treatment. Current Opinion in Clinical Nutrition and Metabolic Care 24(5): 490-497.

7. Welling L, Bernstein LE, Berry GT, Burlina AB, Eyskens F, et al. (2016) International clinical guideline for the management of classic galactosemia: Diagnosis, treatment, and follow-up. Journal of Inherited Metabolic Disease 42(1): 33-47.

8. Berger R, Picciotto D, Angelis D (2020) Mutational spectrum of classic galactosemia in Italian patients. Orphanet Journal of Rare Diseases 15(1): 57.

9. Lai K, Tang M, Wierenga KJ (2021) Advances in understanding and treating classic galactosemia: A focus on potential new therapies. Journal of Inherited Metabolic Disease 44(4): 853-866.

10. Elsas LJ, Lai K, Berry GT (2022) Genotype-phenotype correlation in classic galactosemia: A multicenter cohort study. Clinical Genetics 101(1): 49-59.

11. Berry GT (2021) Galactosemia: When is it a newborn screening emergency? Mol Genet Metab 133(1): 12-18.

12. Calcar SC, Gleason L, Sullivan M (2020) Long-term outcomes of dietary management in classic galactosemia. Molecular Genetics and Metabolism Reports 25: 100670.